Annexon, Inc. (ANNX): Total Liabilities
$65.92M
As of 2025-12-31
$60.01M
As of 2026-06-30
+6.9%
3-year compound annual growth
+41.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $65.92M | +15.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $56.97M | +20.9% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $47.12M | -12.6% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $53.90M | -2.2% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $55.13M | +372.5% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $11.67M | +83.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $6.37M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Annexon, Inc. (ANNX) | 2025-12-31 | $65.92M | +15.7% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $15.65M | +5.9% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $55.04M | +248.4% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $23.43M | +14.8% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $130.07M | -6.1% |
Compare ANNX, TNXP, CTNM, ALT side by side · Screen every company in Pharmaceutical Preparations ↗